Compare ADMA Biologics Inc (ADMA) vs Global X Robotics and Artificial Intelligence ETF (BOTZ) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Global X Robotics and Artificial Intelligence ETF — how do they compare? ADMA Biologics Inc trades at $9.26 (market cap $2.13B), while Global X Robotics and Artificial Intelligence ETF trades at $35.9. The key difference: Global X Robotics and Artificial Intelligence ETF is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | BOTZ | |
|---|---|---|
Market Cap | $2.13B | — |
Sector | Health | — |
52-Week High | $20.38 | $41.63 |
52-Week Low | $7.60 | $31.99 |
Enterprise Value | $2.20B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
BOTZ trades at $36.59, down 2.14% today, with a bullish technical signal from moving averages but neutral oscillators. The ETF focuses on robotics and AI, benefiting from reshoring trends and AI's expansion into physical automation. Recent news highlights robotics as the next trillion-dollar AI theme, with strong media coverage positioning BOTZ as a key player in the humanoid robotics and industrial automation space.
Outlook remains positive due to structural growth in robotics and AI, though valuation metrics are unavailable. Risks include sector concentration and reliance on AI adoption pace. Analyst sentiment is generally favorable, with the ETF well-positioned for long-term automation trends but vulnerable to tech sector volatility and economic cycles.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Global X Robotics and Artificial Intelligence ETF
The fund invests at least 80% of its total assets in the securities of the underlying index. The underlying index is designed to provide exposure to exchange-listed companies in developed markets that are involved in the development of robotics and/or artificial intelligence. The fund is non-diversified.
Read more on BOTZ →
